Dendritic cells (DCs) have received considerable attention as potential targets for the development of novel cancer immunotherapies. However, the clinical efficacy of DC-based vaccines remains suboptimal, largely reflecting local and systemic immunosuppression at baseline. An autologous DC-based vaccine (DCVAC) has recently been shown to improve progression-free survival and overall survival in randomized clinical trials enrolling patients with lung cancer (SLU01, NCT02470468) or ovarian carcinoma (SOV01, NCT02107937), but not metastatic castration-resistant prostate cancer (SP005, NCT02111577), despite a good safety profile across all cohorts. We performed biomolecular and cytofluorometric analyses on peripheral blood samples collected prior to immunotherapy from 1000 patients enrolled in these trials, with the objective of identifying immunological biomarkers that may improve the clinical management of DCVAC-treated patients. Gene signatures reflecting adaptive immunity and T cell activation were associated with favorable disease outcomes and responses to DCVAC in patients with prostate and lung cancer, but not ovarian carcinoma. By contrast, the clinical benefits of DCVAC were more pronounced among patients with ovarian carcinoma exhibiting reduced expression of T cell-associated genes, especially those linked to TH2-like signature and immunosuppressive regulatory T (TREG) cells. Clinical responses to DCVAC were accompanied by signs of antitumor immunity in the peripheral blood. Our findings suggest that circulating signatures of antitumor immunity may provide a useful tool for monitoring the potency of autologous DC-based immunotherapy.

Department of Gynaecology and Obstetrics Leuven Cancer Institute UZ Leuven Leuven Belgium

Department of Gynecology and Obstetrics 1st Faculty of Medicine Charles University University Hospital Bulovka Prague Czech Republic

Department of Gynecology and Obstetrics Charles University 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady Prague Czech Republic

Department of Gynecology and Obstetrics Peking University 3rd Hospital Beijing Hebei Province China

Department of Immunology Charles University 2nd Faculty of Medicine and University Hospital Motol Prague Czech Republic

Department of Oncology Leuven Cancer Institute Laboratory of Gynaecologic Oncology KU Leuven Belgium

Department of Oncology Leuven Cancer Institute Laboratory of Tumor Immunology and Immunotherapy KU Leuven Belgium

Department of Pathology 3rd Faculty of Medicine And University Hospital Kralovske Vinohrady Prague Czech Republic

Department of Pediatric and Adult Rheumatology University Hospital Motol Prague Czech Republic

Gynecologic Oncology Center Department of Obstetrics and Gynecology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Laboratory of Cell Stress and Immunity Department of Cellular and Molecular Medicine KU Leuven Leuven Belgium

Sotio Biotech Prague Czech Republic

The Fingerland Department of Pathology Charles University Faculty of Medicine and University Hospital Hradec Kralove Czech Republic

Zobrazit více v PubMed

Galluzzi L, Chan TA, Kroemer G, Wolchok JD, Lopez-Soto A.. The hallmarks of successful anticancer immunotherapy. Sci Transl Med. 2018;10(459). doi:10.1126/scitranslmed.aat7807. PubMed DOI

Garon EB, Rizvi NA, Hui R, Leighl N, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–14. doi:10.1056/NEJMoa1501824. PubMed DOI

Ansell SM, Lesokhin AM, Borrello I, Halwani A, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–319. doi:10.1056/NEJMoa1411087. PubMed DOI PMC

Huang AC, Postow MA, Orlowski RJ, Mick R, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60–65. doi:10.1038/nature22079. PubMed DOI PMC

Hellmann MD, Callahan MK, Awad MM, Calvo E, et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell. 2018;33(5):853–61 e4. doi:10.1016/j.ccell.2018.04.001. PubMed DOI PMC

Bassez A, Vos H, Van Dyck L, Floris G, et al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat Med. 2021;27(5):820–832. doi:10.1038/s41591-021-01323-8. PubMed DOI

Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7–24. doi:10.1038/s41577-019-0210-z. PubMed DOI

Garg AD, Coulie PG, Van den Eynde BJ, Agostinis P. Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape. Trends Immunol. 2017;38(8):577–593. doi:10.1016/j.it.2017.05.006. PubMed DOI

Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–218. doi:10.1038/s41573-018-0007-y. PubMed DOI

Vitale I, Shema E, Loi S, Galluzzi L. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat Med. 2021;27(2):212–224. doi:10.1038/s41591-021-01233-9. PubMed DOI

Sprooten J, Vankerckhoven A, Vanmeerbeek I, Borras DM, et al. Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer. J Immunother Cancer. 2021;9(11):e003609. doi:10.1136/jitc-2021-003609. PubMed DOI PMC

Nixon AB, Schalper KA, Jacobs I, Potluri S, Wang IM, Fleener C. Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential? J Immunother Cancer. 2019;7(1):325. doi:10.1186/s40425-019-0799-2. PubMed DOI PMC

Sprooten J, Coosemans A, Garg AD. A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology. Oncoimmunology. 2022;11(1):2024692. doi:10.1080/2162402X.2021.2024692. PubMed DOI PMC

Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133–150. doi:10.1038/s41568-019-0116-x. PubMed DOI PMC

Scher HI, Graf RP, Schreiber NA, Jayaram A, et al. Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer. JAMA Oncol. 2018;4(9):1179–1186. doi:10.1001/jamaoncol.2018.1621. PubMed DOI PMC

Wang Z, Duan J, Cai S, Han M, et al. Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel. JAMA Oncol. 2019;5(5):696–702. doi:10.1001/jamaoncol.2018.7098. PubMed DOI PMC

Weiss GJ, Beck J, Braun DP, Bornemann-Kolatzki K, et al. Tumor cell-free DNA copy number instability predicts therapeutic response to immunotherapy. Clin Cancer Res. 2017;23(17):5074–5081. doi:10.1158/1078-0432.CCR-17-0231. PubMed DOI

Hong X, Sullivan RJ, Kalinich M, Kwan TT, et al. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci U S A. 2018;115(10):2467–2472. doi:10.1073/pnas.1719264115. PubMed DOI PMC

Lee EY, Kulkarni RP. Circulating biomarkers predictive of tumor response to cancer immunotherapy. Expert Rev Mol Diagn. 2019;19(10):895–904. doi:10.1080/14737159.2019.1659728. PubMed DOI PMC

Indini A, Rijavec E, Grossi F. Circulating biomarkers of response and toxicity of immunotherapy in advanced non-small cell lung cancer (NSCLC): a comprehensive review. Cancers (Basel). 2021;13(8):1794. doi:10.3390/cancers13081794. PubMed DOI PMC

Zemanova M, Cernovska M, Havel L, Bartek T, et al. Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: a randomized, open-label, phase I/II trial. Cancer Treat Res Commun. 2021;28:100427. doi:10.1016/j.ctarc.2021.100427. PubMed DOI

Rob L, Cibula D, Knapp P, Mallmann P, et al. Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. J Immunother Cancer. 2022;10(1):e003190. doi:10.1136/jitc-2021-003190. PubMed DOI PMC

Fucikova J, Hensler M, Kasikova L, Lanickova T, et al. An autologous dendritic cell vaccine promotes anticancer immunity in ovarian cancer patients with low mutational burden and cold tumors. Clin Cancer Res. pp.OF1–OF13. 2022. doi:10.1158/1078-0432.CCR-21-4413 PubMed DOI

Vogelzang NJ, Beer TM, Gerritsen W, Oudard S, et al. Efficacy and safety of autologous dendritic cell-based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate cancer: the VIABLE Phase 3 randomized clinical trial. JAMA Oncol. 2022;8:546. doi:10.1001/jamaoncol.2021.7298. PubMed DOI PMC

Fucikova J, Moserova I, Truxova I, Hermanova I, et al. High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer. 2014;135(5):1165–1177. doi:10.1002/ijc.28766. PubMed DOI

Fucikova J, Rozkova D, Ulcova H, Budinsky V, et al. Poly I: c-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. J Transl Med. 2011;9:223. doi:10.1186/1479-5876-9-223. PubMed DOI PMC

Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32(18):2847–2849. doi:10.1093/bioinformatics/btw313. PubMed DOI

Wu T, Hu E, Xu S, Chen M, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (N Y). 2021;2(3):100141. PubMed PMC

Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–668. doi:10.1038/s41577-020-0306-5. PubMed DOI PMC

Dall’Olio FG, Marabelle A, Caramella C, Garcia C, et al. Tumour burden and efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2022;19(2):75–90. doi:10.1038/s41571-021-00564-3. PubMed DOI

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–1920. doi:10.1016/S0140-6736(16)00561-4. PubMed DOI PMC

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690. PubMed DOI PMC

Monk BJ, Colombo N, Oza AM, Fujiwara K, et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(9):1275–1289. doi:10.1016/S1470-2045(21)00342-9. PubMed DOI

Beer TM, Kwon ED, Drake CG, Fizazi K, et al. Randomized, double-blind, phase iii trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35(1):40–47. doi:10.1200/JCO.2016.69.1584. PubMed DOI

Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019;4:7. doi:10.1038/s41541-019-0103-y. PubMed DOI PMC

Fucikova J, Palova-Jelinkova L, Bartunkova J, Spisek R. Induction of tolerance and immunity by dendritic cells: mechanisms and clinical applications. Front Immunol. 2019;10:2393. doi:10.3389/fimmu.2019.02393. PubMed DOI PMC

Sprooten J, Ceusters J, Coosemans A, Agostinis P, et al. Trial watch: dendritic cell vaccination for cancer immunotherapy. Oncoimmunology. 2019;8(11):e1638212. doi:10.1080/2162402X.2019.1638212. PubMed DOI PMC

Vacchelli E, Vitale I, Eggermont A, Fridman WH, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology. 2013;2(10):e25771. doi:10.4161/onci.25771. PubMed DOI PMC

Pol J, Bloy N, Buque A, Eggermont A, et al. Trial watch: peptide-based anticancer vaccines. Oncoimmunology. 2015;4(4):e974411. doi:10.4161/2162402X.2014.974411. PubMed DOI PMC

Salmon H, Idoyaga J, Rahman A, Leboeuf M, et al. Expansion and activation of CD103(+) Dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity. 2016;44(4):924–938. doi:10.1016/j.immuni.2016.03.012. PubMed DOI PMC

Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31:563–604. doi:10.1146/annurev-immunol-020711-074950. PubMed DOI PMC

Garg AD, Vandenberk L, Koks C, Verschuere T, et al. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma. Sci Transl Med. 2016;8(328):328ra27. doi:10.1126/scitranslmed.aae0105. PubMed DOI

Sarivalasis A, Boudousquie C, Balint K, Stevenson BJ, et al. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. J Transl Med. 2019;17(1):391. doi:10.1186/s12967-019-02133-w. PubMed DOI PMC

Charles J, Chaperot L, Hannani D, Bruder Costa J, et al. An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial. Oncoimmunology. 2020;9(1):1738812. doi:10.1080/2162402X.2020.1738812. PubMed DOI PMC

Cibula D, Rob L, Mallmann P, Knapp P, et al. Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): a randomized, open-label, phase 2 trial. Gynecol Oncol. 2021;162:652–660. doi:10.1016/j.ygyno.2021.07.003. PubMed DOI

Coosemans A, Decoene J, Baert T, Laenen A, et al. Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course. Oncoimmunology. 2016;5(4):e1111505. doi:10.1080/2162402X.2015.1111505. PubMed DOI PMC

De Bruyn C, Ceusters J, Landolfo C, Baert T, et al. Neo-adjuvant chemotherapy reduces, and surgery increases immunosuppression in first-line treatment for ovarian cancer. Cancers (Basel). 2021;13(23):5899. doi:10.3390/cancers13235899. PubMed DOI PMC

Liang B, Workman C, Lee J, Chew C, et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol. 2008;180(9):5916–5926. doi:10.4049/jimmunol.180.9.5916. PubMed DOI

Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322(5899):271–275. doi:10.1126/science.1160062. PubMed DOI

Deaglio S, Dwyer KM, Gao W, Friedman D, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204(6):1257–1265. doi:10.1084/jem.20062512. PubMed DOI PMC

Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol. 2011;11(2):119–130. doi:10.1038/nri2916. PubMed DOI PMC

Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol. 2009;9(7):480–490. doi:10.1038/nri2580. PubMed DOI PMC

Kandalaft LE, Odunsi K, Coukos G. Immunotherapy in ovarian cancer: are we there yet? J Clin Oncol. 2019;37(27):2460–2471. doi:10.1200/JCO.19.00508. PubMed DOI

Fucikova J, Palova-Jelinkova L, Klapp V, Holicek P, et al. Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents. Trends Cancer. 2022;8:426–444. doi:10.1016/j.trecan.2022.01.010. PubMed DOI

Petroni G, Buque A, Zitvogel L, Kroemer G, Galluzzi L. Immunomodulation by targeted anticancer agents. Cancer Cell. 2021;39(3):310–345. doi:10.1016/j.ccell.2020.11.009. PubMed DOI

Stewart RA, Pilie PG, Yap TA. Development of PARP and immune-checkpoint inhibitor combinations. Cancer Res. 2018;78(24):6717–6725. doi:10.1158/0008-5472.CAN-18-2652. PubMed DOI

Bol KF, Schreibelt G, Gerritsen WR, de Vries IJ, Figdor CG. Dendritic cell-based immunotherapy: state of the art and beyond. Clin Cancer Res. 2016;22(8):1897–1906. doi:10.1158/1078-0432.CCR-15-1399. PubMed DOI

Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23(4):487–500. doi:10.1038/s41590-022-01132-2. PubMed DOI

Coukos G, Tanyi J, Kandalaft LE. Opportunities in immunotherapy of ovarian cancer. Ann Oncol. 2016;27 Suppl 1:i11–i5. doi:10.1093/annonc/mdw084. PubMed DOI PMC

Trial watch: chemotherapy-induced immunogenic cell death in oncology

Mast Cells and Dendritic Cells as Cellular Immune Checkpoints in Immunotherapy of Solid Tumors

Zobrazit více v PubMed

ClinicalTrials.gov
NCT02470468, NCT02107937, NCT02111577